The long-term goal of this project is to increase the cure rate of primary liver cancer by adapting treatment to the individual patient response. This goal will be carried out through two specific aims.
Aim 1 is to complete a phase II clinical trial for patients with HCC in which the dose is based on the individual patient's liver function. We will measure global and regional changes in liver function in patients undergoing radiation therapy for HCC who are ineligible for or have progressed after standard therapy. We will administer 60% of the treatment, wait the month that we have shown is required to express early liver injury, reassess tumor response, liver function, and liver injury to adapt the dose for the rest of treatment, based on a more accurate estimate of that individual patient's risk of toxicity. We will also assess regional response in the tumor. We hypothesize that adapting radiation therapy based on the tumor and uninvolved liver responses assessed during treatment will permit us to achieve a >80% 1 year tumor control rate while causing no greater toxicity than standard therapy.
Aim 2 is to conduct a phase II randomized trial to compare standard therapy (fixed course treatment without adaptation) to the model proposed in Aim 1 that adapts therapy based on the individual patient's response.
Aim 1 will provide the data to Project 4 to help develop a model for treatment that is predicted to maximize tumor response by intensifying treatment to refractory subvolumes of tumor (defined by Project 3), and minimize uninvolved liver injuty by delivering dose through non-functioning regions of the liver, and by knowing the radiation sensitivity of the individual patient. This will be accomplished by replanning treatment after 60% has been delivered based on tumor response and uninvolved liver injury. This arm will be compared in a randomized phase 11 trial to a standard arm using an approach that bases the dose on the volume of uninvolved liver spared (which we developed in an earlier version of this PO-1), but adapts neither tumor nor uninvolved liver dose and dose distribution. We hypothesize that treating patients with adaptive radiation therapy based on the tumor and uninvolved liver responses assessed during treatment will produce superior tumor control at no greater toxicity than the standard arm that gives a fixed dose based on the volume of uninvolved liver irradiated (but does not adapt therapy). The impact of this work is that it will develop a new paradigm for radiation oncology in which treatment is optimized by adapting therapy to the individual patient response, rather than based on the "average patient".

Public Health Relevance

Radiation therapy alone cures only a small fraction of patients with unresectable liver cancer. We propose to improve the cure rate by adapting therapy to the individual patient by assessing midtreatment changes in the patient's tumor and normal tissues. These changes will reveal to us the individual patient's sensitivity to treatment so that we can give more radiation to the aggressive regions of the tumor while avoiding normal functioning liver. Our approach should be vastly superior to basing all treatment on the average patient.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA059827-16A1
Application #
8609640
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (O1))
Project Start
1997-02-01
Project End
2019-04-30
Budget Start
2014-05-15
Budget End
2015-04-30
Support Year
16
Fiscal Year
2014
Total Cost
$342,598
Indirect Cost
$120,562
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Hunter, Klaudia U; Lee, Oliver E; Lyden, Teresa H et al. (2014) Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors. Head Neck 36:120-5
Vainshtein, Jeffrey M; Spector, Matthew E; McHugh, Jonathan B et al. (2014) Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. Oral Oncol 50:513-9
Nazem-Zadeh, Mohammad-Reza; Chapman, Christopher H; Chenevert, Thomas et al. (2014) Response-driven imaging biomarkers for predicting radiation necrosis of the brain. Phys Med Biol 59:2535-47
Stenmark, Matthew H; Cao, Yue; Wang, Hesheng et al. (2014) Estimating functional liver reserve following hepatic irradiation: adaptive normal tissue response models. Radiother Oncol 111:418-23
Hunter, Klaudia U; Schipper, Matthew; Feng, Felix Y et al. (2013) Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. Int J Radiat Oncol Biol Phys 85:935-40
Wilkie, Joel R; Matuszak, Martha M; Feng, Mary et al. (2013) Use of plan quality degradation to evaluate tradeoffs in delivery efficiency and clinical plan metrics arising from IMRT optimizer and sequencer compromises. Med Phys 40:071708
Vainshtein, Jeffrey; Eisbruch, Avraham (2013) Function, muscles, and sparing by IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 85:577-8
Cao, Yue; Wang, Hesheng; Johnson, Timothy D et al. (2013) Prediction of liver function by using magnetic resonance-based portal venous perfusion imaging. Int J Radiat Oncol Biol Phys 85:258-63
Hunter, Klaudia U; Fernandes, Laura L; Vineberg, Karen A et al. (2013) Parotid glands dose-effect relationships based on their actually delivered doses: implications for adaptive replanning in radiation therapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys 87:676-82
Farjam, Reza; Parmar, Hemant A; Noll, Douglas C et al. (2012) An approach for computer-aided detection of brain metastases in post-Gd T1-W MRI. Magn Reson Imaging 30:824-36

Showing the most recent 10 out of 200 publications